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PHARMACOKlNETICS OF OFLOXACIN, RIFAMPICIN , 
ISONIAZID AND PYRAZINAMIDE WHEN ADMINISTERED 
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RAJASEHARAN**, FATHIMA REHMAN, SEKAR L. AND NARAYANAN P.R. 
Tuberculosis Research Centre (ICMR), Chennai - 600 031 
**Madras Medical College, Chennai. 
The present study assesses the bioavailability of Ofloxacin (O) 
following single oral administration of the drug along with Rifampicin 
(R), or Isoniazid (H), or Pyrazinamide (Z) or a combination of three 
drugs. Information on the pharmacokinetics of O in the presence of R, 
H and Z based on the blood concentrations upto 8 hours, on the 
proportions of the doses of the drugs and their metabolites excreted in 
urine upto 8 hours and also the effect of O on the other anti- 
tuberculosis (TB) drugs in terms of absorption and interactions are 
extensively studied. The bioavailability indices of these drugs are 
assessed. The investigation was undertaken in a total of 12 male 
healthy volunteers and each volunteer was investigated on four 
different occasions at weekly intervals. A partially balanced incomplete 
block design was employed and the allocation of O or the drug 
combinations was at random. Plasma concentrations of O, R, H and Z 
were determined. Urinary excretion of these drugs, together with their 
primary metabolites was also determined. Various pharmacokinetic 
parameters were calculated. The results have shown that the 
bioavailability of O is not impaired when administered with other anti- 
tuberculosis drugs like R, H and Z and does not exercise any 
therapeutic penalty. The bioavailability of other anti-TB drugs like R, H 
and Z does not get affected when administered along with O. Human 
bioavailability studies, in general, provide direct straightforward 
information on the degree of absorption and biotransformation of 
drugs. The results of the present study indicate that the 
pharmacokinetic properties of O, R, H and Z as assessed after 
individual and combined administration of these drugs do not get 
affected or altered. Since there are no interactions among these drugs, 
the use of 0 in the treatment of pulmonary tuberculosis is justified. 
Kew Words : Anti-tuberculosis drugs; Bioavailability; Drug 
interactions; Ofloxacin. 
Corresponding Author 
INTRODUCTION Though, the treatment of tuberculosis with 
multidrug therapy witnessed a dramatic 
Tuberculosis has been and continues to be improvement in the control of the disease, 
the leading cause of death world wide from the main problem encountered in 
a single infectious agent, M. tuberculosis. implementing these regimens is the 
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prolonged course of therapy and poor 
compliance. 
The advent of the new quinolone, Ofloxacin 
(O), a synthetic carboxy quinolone has 
broadened rather unexpectedly the 
therapeutic efficacy against infections with 
mycobacteria. 
Studies on the pharmacology of 0 have 
gained importance in view of the suitability 
of this drug for the chemotherapy of 
tuberculosis. This drug is reported to be as 
powerful as R and H and superior to 
streptomycin in terms of bactericidal activity. 
Ofloxacin appears to be as useful as 
ethambutol in the treatment of pulmonary 
tuberculosis 
with H and R 
Since, only limited information is currently 
available on the pharmacokinetic 
interactions of O in the presence of other 
anti-tuberculosis drugs, viz., R, H and Z, this 
study is designed to rigorously characterise 
the interaction potentials between 0 and 
other anti-TB drugs. Therefore, an 
investigation was carried out to obtain 
information on the plasma and urinary 
excretion of 0 alone and in combination 
with other anti-TB drugs mentioned above 
and also to study the effect of O on the 
other anti-TB drugs. 
45-69 kg) were admitted to the study. The 
volunteers were healthy as assessed by 
comprehensive medical history, physical 
examination and laboratory profiles for 
diabetic, renal and hepatic functions. None 
of the subjects was taking any medications 
one week before or during the study for any 
ailment and also are non-alcoholics. 
Informed written consent was obtained from 
the subjects, and the study was approved 
by the Ethical Committee of the Centre. 
” 
Assay for the stated contents of the 
drugs 
Before starting the study, six samples of 
each of drugs (O, R, H & Z) were assayed 
for he stated contents, on five different 
occasions to check for the potency and the 
stated contents. The drugs were obtained 
from the same batch. 
This investigation was carried out in 
collaboration with the Department of 
Pharmacology, Madras Medical College, 
Chennai. 
MATERIALS AND METHODS 
Experimental design 
A partially balanced incomplete block 
design was adopted where the drugs were 
administered to the healthy volunteers, a 
week apart, a random. 
Subjects 
Twelve male healthy volunteers with the 
mean age of 23 years (range 19-27 years) 
and the mean body weight of 56 kg (range 
Conduct of the investigation 
Each volunteer was investigated on 4 
different occasions with the 4 drugs 
administered either alone or in 
combinations (0, R, H, Z, OR, OH, OZ and 
ORHZ) with an interval of atleast one week 
between occasions. The drugs were 
administered on an empty stomach after 
emptying the bladder. The dosages of the 
drugs administered to the volunteers under 
investigation, were approximately 10 mg/kg 
body weight for R (Asojsof Caps. Pvt. Ltd.) 
and 35 mg/kg for Z (Lupin Laboratories); 
the dosages of 0 (Dee-Pharma Ltd.) and H 
(Pfizer) used were 10 mg/kg for the 
subjects weighing <40 kg and 15 mg/kg for 
subjects weighing 2 40 kg. body weight for 
R (Asojsof Caps. Pvt. Ltd.) and 35 mg/kg 
for Z (Lupin Laboratories); the dosages of 0 
(Dee-Pharma Ltd.) and H (Pfizer) used 
were 10 mg/kg for the subjects weighing 
<40 kg and 15 mg/kg for subjects weighing 
> 40 kg. 
Blood sampling 
During each occasion, blood samples were 
drawn at 1,2,3,6 and 8 hours after drugs 
administration. The samples were 
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centrifuged, the plasma were stored at - 
20oC until assay. 
Urine collection 
During each occasion, urine samples 
excreted over the periods 0-8 hours after 
the administration of the drugs were 
collected. The volume of urine samples 
were measured and an aliquot was stored 
at -20°C until the assay of the drugs and 
their metabolites was performed. Urine 
samples were processed for R within 48 
hours following collection, since R is not 
stable in urine (Immanuel et al., 1985). The 
estimation of free H, isonicotinic acid and 
acetylisoniazid, and of Z and pyrazinoic 
acid, were carried out within a week, as it 
was found that these drugs and their 
metabolites are stable in urine for at least a 
week. The excretion of creatinine was also 
undertaken to check for the completeness 
of urine collection by each volunteer. 
The % dose excreted as 0, R, H and their 
metabolites, and of Z plus pyrazinoic acid, 
was calculated based on the urine samples 
collected upto 8 hours. 
Assay methods 
Ofloxacin concentrations in plasma and 
urine were determined by the plate diffusion 
method by Prema Gurumurthy 
et al. (1998), employing a strain of 
Escherichia coli. 
Plasma total R concentrations were 
determined by the plate diffusion method of 
Dickinson et al. (1 974) employing a strain of 
Staphylococcus aureus, resistant to 
streptomycin and other antibiotics. Urinary 
excretion of total R was estimated 
according to the procedure described by 
Chandra lmmanuel et al. (1985). 
Plasma H was estimated by the 
spectrophotofluorimetric method of Olson 
et al. (1977). Urinary excretion of H as total 
INA (after conversion of the free drug and 
its metabolites to INA) was estimated 
according to the method of Ellard and 
Gammon (1 976). 
Pyrazinamide in plasma and Z and PZC in 
urine were estimated by the 
spectrophotometric method of Prema 
Gurumurthy et al. (1980). 
Pooled horse plasma and pooled normal 
urine were used for the preparation of 
standard solutions of O,R,H and Z with 
each assay run, appropriate blank samples 
were processed simultaneously. Also, fresh 
samples were processed in duplicate or 
quadruplicate after coding along with the 
test samples with each assay run. 
The proportions of the doses of 0, R, H and 
their metabolites, and Z and its metabolite 
were calculated. Creatinine estimation on all 
the urine samples was determined by the 
calorimetric method based on Jaffe's 
reaction (Brod et al., 1948). 
All estimations (plasma and urine) were 
undertaken after coding of the samples. 
The study was double-blind, i.e., neither the 
volunteers nor the technical personnel knew 
the identity of the samples and the technical 
personnel was also unaware of the hour of 
collection .
Pure 0, R, Z and ion exchange resin were 
from Sigma Chemical Company, St. Louis, 
MO, USA. Pure H from May & Baker Ltd., 
Nutrient agar and nutrient broth were 
products of Difco Laboratories, Detroit, MI, 
USA and all the other chemicals used were 
of analytical grade. The strain of E. Coli 
used was a clinical isolate and the strain of 
S. aureus was kindly supplied by 
Prof.D.A. Mitchison. 
Kinetics and statistical analyses 
On each series of plasma concentrations, 
the pharmacokinetic variables such as the 
peak concentration (C-max), the time taken 
to attain the peak concentrtion (t-max), the 
area under the time-concentration curve 
(AUC), and half-life (t1/2) (using the formula 
© Publication of Indian Association of Biomedical Scientists 15 
PREMA GURUMURTHY et al., 
log 2/slope) were calculated from the 
plasma concentrations. Further, the 
proportions (%) of the dose excreted in the 
urine collected over the periods 0-8 hrs. 
was also calculated on the basis of the 
concentrations in urine. 
Bioavailability of O, R, H and Z for each of 
the combinations has been expressed as 
an index (BI) and is the ratio of AUC or the 
proportion of the dose (%) excreted in urine 
with the combinations to the respective 
control values obtained after the 
administration of O, R, H and Z alone. 
RESULTS AND DISCUSSION 
Ofloxacin seems to be absorbed completely 
after administration of a single oral dose of 
600 mg. Peak plasma concentrations were 
attained rapidly within 1.25-1.80 hours. The 
mean serial plasma concentrations of 0 
when administered alone and in 
combination with other anti-TB drugs 
namely R, H and H is shown in 
Figure 1. Cmax values of 0 following the 
. single oral dose were 7.14, 6.98, 7.19, 6.06 
and 6.38 µg/ml respectively when O was 
given alone and in combination viz. OR, 
OH, OZ and ORHZ. The differences 
between these groups in the mean 0 
concentrations when administered alone 
and in combination were not statistically 
significant. The plasma concentrations of O 
are generally well in excess of the MIC 
values for Gram + ve bacteria within the 
spectrum of activity of 0. 
Several pharmacokinetic variables, such as 
peak concentration, coverage, area under 
the time concentration curve (AUC) and 
half-life were calculated based on the 
plasma concentrations of 0 at different time 
points (Table 1). When O was administered 
in combination with all the other three drugs, 
a significant difference in the coverage was 
of served. The corresponding values for the 
groups, 0 alone, OR, OH, OZ and ORHZ 
being 20.27, 23.51, 24.45, 24.37 and 34. 
46 µg/ml.hrs. respectively. 
Similarly, the half-life of 0 is not altered 
when administered with R, H and Z alone. 
When 0 is administered with all the three 
anti-tuberculosis drugs, the half-life of 0 is 
significantly increased. The half-life of O 
ranges from 5.29, 6.02, 6.08, 6.51 and 
10.00 hours, when 0 was administered 
alone and in combination with R, H, Z alone 
and with all the three drugs (O,R,H and Z). 
There are no significant differences in the 
AUC (area under the time-concentration 
curve) of 0 when administered alone and in 
combination with other anti-tuberculosis 
drugs. The auc VALUES OF o BEING 
27.49, 31.51, 32.08, 27.86 AND 27.98 
µg/Ml.hours respectively when O alone, OR, 
OH, OZ and ORHZ were given. 
The mean proportions of the dose excreted 
as 0 in urine, collected over the 0-8 hr. 
period and after the administration of 0 
either alone or in combination with various 
anti-tuberculosis drugs are given in Figure 
2. The proportions (%) of the dose excreted 
as 0 in urine were 40.98, 37.20, 46.83, 
39.29 and 35.68% respectively of 0 alone, 
OR, OH, OZ and ORHZ which were 
statistically non-significant between the 
groups. Thus, the bioavailability of O is not 
affected by the coadministration of other 
anti-TB drugs. While investigating the effect 
of R,H and Z on 0, it was also felt essential 
to find out whether O will be affecting the 
bioavailability of other drugs, since O alone 
is not administered to tuberculosis patients 
but and always in combination with other 
potent drugs like R,H and Z. 
The mean serial plasma concentrations of 
R at different time points after oral 
administration of the drug was given in 
Figure 3. The C-max values of R were 
11.71, 9.62 and 9.18 µg/ml respectively 
when R was given alone, in combination 
with O alone and together with all the three 
drugs namely, O, H and Z respectively. The 
differences in the plasma peak 
concentrations between the groups were 
non-significant, although the highest 
concentrations of R were obtained after the 
second hour when R was given alone and 
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in the third hour when combined with O,H 
and Z. 
Based on the plasma concentrations of R at 
different time points, several 
pharmacokinetic variables were calculated 
and half-life, when given alone and in 
combinations, remain unaltered and it was 
non-significant, indicating that there are no 
drug interactions when R was combined 
with O and other anti-tuberculosis drugs. 
The mean proportions (%) of the dose 
excreted as total R in urine were 16.08, 
14.49 and 14.77% respectively when R was 
administered alone or in combination with 0 
and when all the four drugs are given 
(Figure 4). The results have shown that the 
differences between the means of the 
different groups the means of the different 
groups containing R were not statistically 
significant. 
Computing the results obtained for H, the 
mean serial plasma concentrations of H, 
when given alone and in combination with O 
alone or with all the other drugs namely O,R 
and Z at different time points are given in 
figure 5. The mean peak concentrations of 
H in plasma are 11.80, 11.57 and 13.77 
µg/ml respectively when given alone, with O 
and with all the other three drugs. Isoniazid 
was rapidly absorbed in the first hour itself 
when given either alone or in combination 
(OH and OHRZ). There are no significant 
differences in the concentrations of H 
between the groups. 
Similar to R, there are no significant 
differences in the various pharmacokinetic 
differences in the various pharmacokinetic 
parameters calculated (Table 3) based on 
the mean serial plasma concentrations of H 
at different time points, between the groups. 
There are marked increases in the AUC of 
H when H was given with all the other three 
anti-tuberculosis drugs (p<0.021). Whereas 
when H was given with O alone, there are 
no significant differences in the AUC, 
coverage, half-life, T-max and C-max. 
Isoniazid is estimated in the urine as its 
metabolite, isonicotinic acid (INA). The 
proportions (%) of the doses excreted in 
urine as INA are 59,49.32 and 44.68% 
respectively when H is given alone or with 0 
and with all the other three drugs in 
combinations. The results show that there 
are not significant differences in the 
proportions of the doses excreted when 
given either alone or in combination with 0 
and other drugs (Figure 6). 
The mean serial plasma concentration of Z 
at different time points after a single oral 
administration of Z is given in figure 7. The 
highest concentrations of Z are obtained in 
the third hour (ranges from 2.5 - 3.5 hours), 
when given alone and in combinations of Z 
are 47.62, 50.90 and 49.58 µg/ml 
respectively when Z is given alone, along 
with O and with all the other three drugs 
(viz. O, H and R). The results indicate that 
the bioavailability of Z is not affected when 
administered along with other 
antituberculosis drugs, particularly with O. 
The differences between the groups in the 
Z concentrations are not significant 
statistically. 
Based on the plasma estimates of Z, 
pharmacokinetic parameters are calculated 
(Table 4). The AUC remains the same 
when Z is administered with other drugs, 
whereas the coverage and half-life of Z are 
significantly increased when administered 
with all the three antituberculosis drugs. 
This is not due to 0 because when Z 
administered with 0, statistically there is no 
significant difference when compared to the 
group which received Z alone. Moreover the 
significant increase in AUC and half-life in 
the group, which received all the four drugs, 
may be due to population size and hence 
the variability. Thus, the results indicate that 
there are no drug interactions when Z is 
administered with O. 
The mean proportions of the dose excreted 
in the urine as Z and PZC, collected over 
periods 0-8 hr. after the administeration, 
either alone or in combinations, are given in 
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Figure 8. Pyrazinamide gets excreted via 
kidneys as Z and its metabolite PZC. The 
proportions of dose excreted as Z are 6.27, 
4.34 and 10.43% and as PZC, 14,46, 11.09 
and 11.44% respectively when Z is 
administered alone, in combination with O 
either alone and together 0, R and H. The 
data clearly show that there are no 
significant differences in the excretion of the 
dose as Z and PZC, when Z is given alone 
and in combination with 0. 
Tuberculosis has been declared a global 
emergency by the WHO. This 
unprecedented declaration has prompted 
predominantly by two developments; the 
resurgence of tuberculosis in the west and a 
number of outbreaks of multi-drug resistant 
tuberculosis (MDR-TB) in many parts of the 
world. 
Tuberculosis requires effective 
chemotherapy, which can be achieved with 
regimens containing a number of drugs 
given separately or in fixed dose 
combinations. 
Tuberculosis research centre has been 
conducting controlled clinical trials in the 
chemotherapy of tuberculosis. The 
management of MDR-TB is a challenging 
problem. The treatment is less effective, 
more toxic and much more expensive 
compared to treatment of drug susceptible 
to tuberculosis. Therefore, the prevention of 
the emergence of drug resistance is of 
paramount importance. There is an urgent 
need for research no develop drugs with 
antimycobacterial activities. 
Recently, O had proved to be a particularly 
valuable addition to the available anti- 
tuberculosis drugs. Ofloxacin is a 
fluorinated quinolone with a broad spectrum 
of activity against Gram +ve and Gram -ve 
bacteria (Sato et al., 1982). The 
effectiveness of 0 against Mycobacterium 
tuberculosis was studied by Crowle et al., 
1988 and their results confirm its clinical 
usefulness as published by others that it 
should be an useful anti-tuberculosis drug 
with a minimum inhibitory concentration of 
1.0 µg/ml. 
Earlier studies reveal the rationale for 
combining 0 with other anti-tuberculosis 
drugs and the improvements that can be 
expected to result from its use in anti- 
tuberculosis chemotherapy. Human 
bioavailability studies provide direct, 
straightfoward information about the drugs 
whose vital role in chemotherapy is well 
established. 
The pharmacokinetics of O are assessed 
by almost its complete bioavailability (95- 
100%). The studies conducted by Lode et 
al., 1987, confirm these findings. Even 
when 0 is administered together with other 
anti-tuberculosis drugs, the 
pharmacokinetic properties of 0 is not 
modified and does not exercise any 
therapeutic penalty. 
The results of this study correlate with the 
hypothesis of complete independence 
between the drugs, as witnessed by a lack 
of negative pharmacokinetic drug 
interactions. Thus, our findings suggest that 
0 and other anti-tuberculosis drugs do not 
interfere with each other in terms of 
absorption, distribution and metabolism. 
It needs to be emphasized that the methods 
employed for the estimation of 0, R, H and 
Z and their metabolites in plasma and urine 
are very simple, precise, sensitive, specific, 
reproducible and do not require 
sophisticated equipments. Good 
bioavailability leading to adequate plasma 
and tissue concentrations of 0 (and other 
drugs) is an absolute prerequisite for the 
success of treatment of tuberculosis. It has 
been postulated that peak plasma 0 
concentrations should be 3.14 ± 0.53 µg/ml 
with a single oral dose of 400 mg for good 
therapeutic response (Yuk et al., 1991). 
Evidence preserved in this report suggests 
when O is administered together with all the 
other three anti-tuberculosis drugs viz., R, H 
and Z respectively, the results of our study 
show that the pharmacokinetic parameters 
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Fig.1: Mean plasma concentration - time profiles 
of ofloxacin when given alone and in combinations 
Drug(s) 
Fig.2: Urinary excretion of ofloxacin 
Fig.3: Mean plasma concentration - time profiles 
of rifampicin when given alone and in combinations 
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Fig.7: Mean plasma concentration - time profiles 
of pyrazinamide when given alone and in combinations 
Fig. 8: Urinary excretion of PZA and PZC 
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ORHZ O OR OH OZ 
Para meter n=12 n=6 n=5 n=9 n=4 
C-max (µg/ml) 7.14 ± 1.44 6.98 ± 1.57 7.19 ± 2.17 6.06 ± 0.93 6.38 ± 1.45 
T-max (hrs.) 1.25 ± 0.45 1.67 ± 0.82 1.80 ± 0.84 1.67 ± 0.71 1.50 ± 1.00 
Half life (hrs.) 5.21 ± 1.69 6.02 ± 1.20 6.08 ± 2.22 6.51 ± 1.81 10.00 ± 5.23 
Coverage (hrs.) 20.27 ± 6.09 23.51 ± 5.79 24.45 ± 8.01 24.37 ± 7.06 34.46 ± 16.29 
AUC (0-8 hrs.) 27.49 ± 5.74 31.5 ± 12.74 32.08 ± 7.89 27.86 ± 6.05 27.98 ± 13.22 
(µg/ml.hrs) 
Table 1 : Pharmacokinetics of ofloxacin in plasma when given alone and in combinations 
Para m et er R OR ORHZ 
n=7 n=5 n=4 
C-max (µg/ml) 11.71 + 4.76 9.61 ± 2.92 9.18 ± 4.25 
T-max (hrs.) 1.71 + 0.76 2.40 ± 0.89 2.25 ± 0.96 
Half life (hrs.) 6.53 + 4.42 8.88 ± 8.40 5.58 ± 0.82 
Coverage (hrs.) 27.29 + 13.88 24.80 ± 3.98 
AUC (0-8 hrs.) 43.51 + 13.18 
(µg/ml. hrs.) 
9.74 ± 21.00 
Table 2 : Pharmacokinetics of rifampicin in plasma when given alone and in combinations 
© Publication of Indian Association of Biomedical Scientists 22 
43.09 ± 10.91 
36.79 ± 28.75 
PHARMACOKINETICS 
H OH ORHZ 
n=8 n=5 n=4 Parameter 
C-max (µg/ml) 11.80 ± 3.08 11.57 ± 2.51 13.77 ± 1.71 
T-max (hrs.) 1.00 ± 0.00 1.00 ± 0.00 1.33 ± 0.58 
Half life (hrs.) 2.85 ± 0.88 2.80 ± 1.08 3.71 ± 0.61 
Coverage (hrs.) 17.63 ± 5.23 17.27 ± 5.93 24.00 ± 2.93 
AUC (0-8 hrs.) 43.20 ± 12.08 42.73 ± 12.36 63.90 ± 4.84 
(µg/ml .hrs.) 
Table 3 : Pharmacokinetics of isoniazid in plasma when given alone and in combinations 
Parameter Z OZ ORHZ 
n= 10 n = 7  n=4 
Cmax (µg/ml) 47.62 ± 10.62 51.97 ± 16.82 49.58 ± 3.81 
2.43 ± 0.53 3.50 ± 1.73 
Half life (hrs.) 8.86 ± 4.30 9.96 ± 5.57 16.02 ± 8.64 
Coverage (hrs.) 22.28 ± 9.19 24.69 ± 14.33 41.09 ± 22.76 
T-max (hrs.) 3.20 ± 1.62 
202.94 ± 67.28 191.51 ± 113.84 226.39 ± 54.24 (µg/ml.hrs) 
Table 4 : Pharmacokinetics of pyrazinamide in plasma when given alone and in combinations. 
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like coverage and half-life are significantly 
increased, thereby rendering the 
bioavailability of O to the system for a longer 
period. This may at times lead to drug 
toxicity and may require adjustment of drug 
dosage when given in combinations. 
In the ORHZ group, the pharmacokinetic 
parameters calculated based on the plasma 
estimates were with lots of individual 
variations, although the differences in the 
peak concentrations and AUC are not 
statistically significantly when O alone is 
compared with ORHZ. This is rather 
surprising that for any bioavailability studies, 
peak and AUC are important determinants 
for assessing proper absorption and 
metabolism of the drugs. Nevertheless, 
these differences in both coverage and half- 
life cannot be ignored. This could mainly 
due to the differences among volunteers in 
terms of absorption and metabolism. 
Sample size i.e. the number of volunteers 
tested is very small. Due to the reasons 
indicated above, these results could well be 
interpreted if larger volunteers are included 
in the ORHZ group. 
Similarly our reports have also shown that 
the bioavailability of other anti-tuberculosis 
drugs viz., R, H and Z do not get affected or 
altered when administered with O. 
The results demonstrate that the absorption 
of O, R, H and Z in healthy volunteers is not 
modified when given in combination. It is 
well known that the therapeutic value of any 
drug depends on proper absorption, 
metabolism and excretion. 
The proportions of the doses excreted in 
urine over 8 hour period are compared with 
the plasma kinetics and it was found that 
there are no significant differences between 
the blood kinetics and renal clearance of all 
the four drugs. It can, therefore, be 
concluded that for bioavailability studies 
involving these drugs, invasive blood 
collection can be replaced by simple non- 
invasive urine collections. Ofloxacin 
undergoes a limited degree of 
biotransformation. In individuals with normal 
renal function, less that 5% of O is excreted 
in the urine as metabolites (Lode et al., 
1987). Three metabolites have been 
identified, Ofloxacin glucuronide, 
Desmethyl-Ofloxacin glucuronide, 
Desmethyl-Ofloxacin and Ofloxacin-N- 
Oxide (Borner et al., 1986a). Such a low 
concentrations of the metabolites are 
present even in renal failure and it is of 
negligible clinical importance white et al., 
1988). Our results strengthen the previous 
reports (Abdallah et al., 1995) that the 
addition of O to regular tuberculosis 
treatment regimen would reduce the 
therapeutic period. 
Ofloxacin may be used as a second-line 
drug in the treatment of tuberculosis- 
resistant organism. But, several studies 
have proved that O can be combined with 
first-line anti-tuberculosis-drugs in the 
treatment of primary cases of pulmonary 
tuberculosis patients. Our findings also 
support that O may be used along with 
other first-line anti-tuberculosis drugs in the 
treatment of pulmonary tuberculosis. 
Usually the problem encountered in 
combination therapy would be drug 
interactions. Our data show that when O is 
combined with R, H and Z, the bioavailability 
of either O or other -anti-tuberculosis drugs 
does not get altered or affected, thereby 
facilitating effective treatment. Since there 
are no drug interactions, the use of O in the 
treatment of pulmonary tuberculosis is 
justified. 
Ofloxacin is completely absorbed and has a 
long half-life, an apparent high volume of 
distribution, predominant renal elimination 
and only limited biotransformation. The 
addition of O to regular tuberculosis 
treatment regimen would reduce the 
therapeutic period and render the patient 
productive. Patients treated with O in the 
multiple regimens are cured with minimal or 
no side effects. 
However, further studies, in patients, in a 
larger population, by administering multiple 
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doses or with different dosages, are 
required to provide a better definition of the 
efficacy of O in the treatment of 
mycobacterial infections. However, multiple 
doses of administration of O do not appear 
to result in significant accumulation 
(Farinotti et al., 1988). 
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